Annexon Biosciences (ANNX) Reiterated at Overweight by Cantor Fitzgerald

Cantor Fitzgerald analyst Pete Stavropoulos reiterated an Overweight rating on Annexon Biosciences (NASDAQ: ANNX).

The anayst commented, "We caught up with ANNX management to discuss the regulatory activity and the MAA filing for tanruprubart (ANX005) in Guillain-Barré syndrome (GBS), and the upcoming ARCHER II P3 vonaprument (ANX007) readout in geographic atrophy (GA). ANNX reached a key regulatory milestone with the submission of an MAA in the EU for tanruprubart in GBS, marking the company’s first regulatory filing that we believe is supported by a robust dataset."

For an analyst ratings summary and ratings history on Annexon Biosciences click here. For more ratings news on Annexon Biosciences click here.

Shares of Annexon Biosciences closed at $6.19 yesterday.

You May Also Be Interested In

• Goldman Sachs Adjust Monthly US Director's Cut List
• JPMorgan Downgrades Li Ning Co. Ltd. (2331:HK) (LNNGF) to Neutral
• Mizuho: 'we believe CMG's cycle of lower margin revisions remains in the rear-view mirror'